Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bhutia, Yangzom Doma ^a   Hung, Sau Wai ^a   Krentz, Madeline ^a   Patel, Dimal ^a   Lovin, Dylan ^a   Manoharan, Radhika ^a   Thomson, J Michael ^b   Govindarajan, Rajgopal ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; MICRORNA; ONCOPROTEIN; PROTEIN LIN 28; PROTEIN SET; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M2; RNA BINDING PROTEIN; RNA PRECURSOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOGENESIS; CANCER CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN CAPAN 1; CELL STRAIN MIA; CELL STRAIN PACA 2; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; GENE LIBRARY; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LET 7A GENE; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; RNA BINDING; RNA PROCESSING; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL LINE; CELLS, CULTURED; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE CHAPERONES; HUMANS; MICRORNAS; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA INTERFERENCE; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS;

AGOUTI PACA;

EID: 84872412062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053436     Document Type: Article

References (50)

1. Hung SW, Mody HR, Govindarajan R, (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer- A therapeutic challenge. Cancer Lett 320: 138-49.
2. Bayraktar S, Bayraktar UD, Rocha-Lima CM, (2010) Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 16: 673-82.
3. Goan YG, Zhou B, Hu E, Mi S, Yen Y, (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-7.
4. Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, et al. (2007) Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 42: 389-94.
5. Zhou B, Mo X, Liu X, Qiu W, Yen Y, (2001) Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 95: 34-42.
6. Bergman AM, Pinedo HM, Peters GJ, (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33.
7. Chabes AL, Pfleger CM, Kirschner MW, Thelander L, (2003) Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci U S A 100: 3925-9.
8. Chabes AL, Bjorklund S, Thelander L, (2004) S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem 279: 10796-807.
9. Liu X, Zhou B, Xue L, Qui W, Shih J, et al. (2004) Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol 67: 1499-511.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE, (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23: 1539-48.
11. Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y, (2006) Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep 15: 1299-304.
12. Sayed D, Abdellatif M, (2011) MicroRNAs in Development and Disease. Physiol Rev 91: 827-87.
13. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ, (2011) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81: 103-222011.
14. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, et al. (2011) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
15. Lu J, Getz G, Miska EA, Alvarez- Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-8.
16. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. (2006) Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20: 2202-7.
17. Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, et al (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-12.
18. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, et al. (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-22.
19. Oh JS, Kim JJ, Byun JY, Kim IA, (2010) Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 76: 5-8.
20. Zhou B, Liu X, Mo X, Xue L, Darwish D, et al. (2003) The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 63: 6583-94.
21. Kuo ML, Hwang HS, Sosnay PR, Kunugi KA, Kinsella TJ, (2003) Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J 9: 277-85.
22. Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, et al. (2009) let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 20: 831-44.
23. Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R, (2011) CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 71: 1825-35.
24. Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor- Anglada M, et al. (2008) Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol Gastrointest Liver Physiol 295: G570-80.
25. Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, et al. (2009) Let-7 overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem 284: 6605-9.
26. Chabes A, Thelander L, (2000) Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J Biol Chem 275: 17747-53.
27. Roush S, Slack FJ, (2008) The let-7 family of microRNAs. Trends Cell Biol 18: 505-16.
28. Van Wynsberghe PM, Kai ZS, Massirer KB, Burton VH, Yeo GW, et al. (2011) LIN-28 co-transcriptionally binds primary let-7 to regulate miRNA maturation in Caenorhabditis elegans. Nat Struct Mol Biol 18: 302-8.
29. Viswanathan SR, Daley GQ, (2010) Lin28: A microRNA regulator with a macro role. Cell 140: 445-9.
30. Michlewski G, Caceres JF, (2010) Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis. Nat Struct Mol Biol 17: 1011-8.
31. Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang YC, et al. (2011) Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 26: 1003-10.
32. Meng F, Glaser SS, Francis H, DeMorrow S, Han Y, et al. (2012) Functional Analysis of microRNAs in Human Hepatocellular Cancer Stem Cells. J Cell Mol Med. 6: 160-73.
33. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, et al. (2011) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of MDR1. Int J Cancer 130: 1787-97.
34. Wong A, Soo RA, Yong WP, Innocenti F, (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41: 77-88.
35. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, et al. (2007) Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96: 457-63.
36. Vasudevan S, Tong Y, Steitz JA, (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931-4.
37. Trujillo RD, Yue SB, Tang Y, O'Gorman WE, Chen CZ, (2010) The potential functions of primary microRNAs in target recognition and repression. EMBO J 29: 3272-85.
38. Saletta F, Rahmanto YS, Richardson DR, (2010) The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta. 1806: 275-86.
39. Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y, (2009) Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 284: 18085-95.
40. Kuschak TI, Kuschak BC, Taylor CL, Wright JA, Wiener F, et al. (2002) c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene. Oncogene 21: 909-20.
41. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, et al. (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109: 182-8.
42. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, et al. (2011) Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predicts poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 17: 5793-800.
43. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, et al. (2005) Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93: 233-41.
44. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, et al. (2005) RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 11: 3433-8.
45. Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, et al. (2008) Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33: 1187-94.
46. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H, (2007) Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67: 10117-22.
47. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, et al. (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67: 1419-23.
48. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, et al. (2011) Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30: 2504-13.
49. Barh D, Malhotra R, Ravi B, Sindhurani P, (2010) MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17: 70-80.
50. Garzon R, Marcucci G, Croce CM, (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-89.